Senti Bio, hot off $645M Spark pact, tees up in-house manufacturing for natural killer cell therapies

Retrieved on: 2021-06-25 15:33:45

Tags for this article:

Click the tags to see associated articles and topics

Senti Bio, hot off $645M Spark pact, tees up in-house manufacturing for natural killer cell therapies. View article details on hiswai:

Excerpt

Roche's Spark Therapeutics recently forged a $645 million-plus biobucks pact with Senti to apply its gene circuit tech to next-gen gene therapies.

Article found on: www.fiercepharma.com